Jackie Hunter
Board Director at BenevolentAI
Meet Jackie Hunter
Hunter has over thirty years of experience in the bioscience research sector, working across academia and industry, including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline.
“BenevolentAI leverages machine learning to help scientists view and reason across all of the world’s available biomedical information to solve complex drug discovery challenges. Last year, the company identified baricitinib as a treatment for COVID-19, which later won FDA approval for use in hospitalized patients. Post-pandemic, we should expect industry conversations to revolve around how we use AI to improve future health systems and revolutionize the drug discovery process. Another topic that will dominate the industry post-COVID is how we improve and unblock approval processes for future therapies and vaccines. We have seen how approvals can be expedited with rolling data reviews and large data trials in the pandemic, and, as a result, we have witnessed huge scientific leaps in vaccine development.”